Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Checklist to Prevent MRSA Surgical Site Infections
NCT02216227Completed
- Sponsor
- VA Office of Research & Development
- Start
- Apr 2014
- Primary completion
- Feb 2021
- Modality
- Reversible Covalent Inhibitors, Cyclic Peptides, Antimicrobial Peptides
- Countries
- 1
01
Overview
Open-label trial of mupirocin, chlorhexidine, cefazolin, vancomycin and povidone-iodine in surgical site infection (SSI) (3 arms), sponsored by VA Office of Research & Development. Primary endpoint: Participants With Superficial and Deep/Organ Space MRSA Infections at 90 days. Started Apr 2014; status: completed.
02
Drugs
mupirocinchlorhexidinecefazolinvancomycinpovidone-iodine
03
Conditions
surgical site infection (SSI)
Beyond the preview
Go deeper on NCT02216227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02216227.